Steven L. Werlin

Steven L. Werlin

Auto-generated profile, based on publicly available information

Steven L. Werlin

Medical College of Wisconsin

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2003 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SWSteven L. Werlin
Steven L. Werlin
SKSubra Kugathasan
Subra Kugathasan
BFBrenda Cowan Frautschy
Brenda Cowan Frautschy

1 May 2006 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
VBVincent Biank
Vincent Biank
SWSteven Werlin
Steven Werlin

1 September 2010 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
NVNarayanan Venkatasubramani
Narayanan Venkatasubramani
GTGrzegorz Telega
Grzegorz Telega
SWSteven L Werlin
Steven L Werlin

29 May 2014 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
NRNisreen Rumman
Nisreen Rumman
MSMutaz Sultan
Mutaz Sultan
KEKhalil El-Chammas
Khalil El-Chammas
VGVi Goh
Vi Goh
NSNita Salzman
Nita Salzman
SWSteven Werlin
Steven Werlin
There is increasing evidence that intestinal inflammation plays a major role in gastrointestinal symptoms in cystic fibrosis (CF). Fecal calprotectin is a marker that is elevated in several gastrointestinal inflammatory diseases, but little is known about its value in CF. We aimed to look for associations of elevated fecal calprotectin among CF patients and whether its level correlates with the clinical manifestations of CF.

1 June 2007 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
NTNeelesh A. Tipnis
Neelesh A. Tipnis
SWSteven L. Werlin
Steven L. Werlin

1 October 2006 in Pediatrics
Verified
Journal Article
Closed access
PDF file
SWSteven L. Werlin
Steven L. Werlin
DFDaryl L. Fish
Daryl L. Fish
OBJECTIVE. Our goal was to characterize valproic acid–associated pancreatitis in children.PATIENTS AND METHODS. The charts of all patients with pancreatitis (diagnosed by using strict criteria) associated with valproic acid during a 10-year period were reviewed. Clinical and laboratory results were abstracted.RESULTS. Twenty-two patients with valproic acid–associated pancreatitis were seen during the study period. Symptoms were similar to those of patients with pancreatitis from other etiologies and included abdominal pain/tenderness (83%), vomiting/retching (74%), abdominal distention (30%), and fever/chills (26%). Valproic acid levels were in the therapeutic range in all but 1 patient. The mean duration of therapy before the onset of pancreatitis was 32 months. The serum lipase level was >3 times the reference value in all patients, but the serum amylase level was not significantly elevated in 31% of the patients tested. Imaging studies altered clinical management in only 1 patient. The length of stay was generally brief (mean: 8 days). Two patients died. Of the 5 patients who were rechallenged, 4 had relapses.CONCLUSIONS. Valproic acid–associated pancreatitis does not depend on valproic acid serum level and may occur any time after the onset of therapy. The serum lipase level is more sensitive than the serum amylase level and should be obtained when pancreatitis is suspected. Early imaging studies did not change clinical management. Rechallenge with valproic acid is dangerous and should be avoided.